Finerenone: A new mineralocorticoid receptor antagonist without hyperkalemia: An opportunity in patients with CKD?

Current Hypertension Reports

Volumn 18, Issue 5, 2016, Pages

  Haller, Hermann ^a   Bertram, Anna ^a   Stahl, Klaus ^a   Menne, Jan ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Alsosterone; Epleronene; Fibrosis; Finererone; Mineralocorticoidreceptors; Oxidative stress; Spironolactone; Tissue injury

Indexed keywords

EPLERENONE; FINERENONE; MINERALOCORTICOID RECEPTOR; PLACEBO; POTASSIUM; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST; NAPHTHYRIDINE DERIVATIVE;

ALBUMINURIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT WITHDRAWAL; ANIMAL; METABOLISM; RENAL INSUFFICIENCY, CHRONIC;

ANIMALS; HUMANS; HYPERKALEMIA; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NAPHTHYRIDINES; RECEPTORS, MINERALOCORTICOID; RENAL INSUFFICIENCY, CHRONIC;

EID: 85008474296     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-016-0649-2     Document Type: Article

References (90)

1. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension. 2005;46:1227-35. Comprehensive review on the molecular mechanisms of mineralocorticoids.
2. Fuller PJ, Yao Y, Yang J, Young MJ. Mechanisms of ligand specificity of the mineralocorticoid receptor. J Endocrinol. 2012;213: 15-24.
3. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet J-P. Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase in the human heart. Circulation. 1995;92(2):175-82.
4. Viengchareun S, Le Menuet D, Martinerie L, Munier M, Pascual-Le Tallec L, Lombès M. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal. 2007;5, e012.
5. Bader M. Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy. Annu Rev Pharmacol Toxicol. 2010;50: 439-65. This review by an international expert on RASS system gives a comprehensive overview on established and future therapeutic targets. Provides insight into molecular studies of the RAAS system.
6. Taves MD, Gomez-Sanchez CE, Soma KK. Extra-adrenal glucocorticoids and mineralocorticoids: evidence for local synthesis, regulation, and function. Am J Physiol Endocrinol Metab. 2011;301: E11-24.
7. Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J. 2006;20:1546-8.
8. Park YM, Lim BH, Touyz RM, Park JB. Expression of NAD(P)H oxidase subunits and their contribution to cardiovascular damage in aldosterone/salt-induced hypertensive rat. J Korean Med Sci. 2008;23(6):1039-45.
9. Michea L, Villagrán A, Urzúa A, Kuntsmann S, Venegas P, Carrasco L, et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats. Hypertension. 2008;52(2):295-300.
10. Mayyas F, Alzoubi KH, Van Wagoner DR. Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone pro-motes oxidative stress and atrial structural/electrical remodeling. Int J Cardiol. 2013;168:5135-42.
11. Karbach S, Wenzel P, Waisman A, Munzel T, Daiber A. Enos uncoupling in cardiovascular diseases-the role of oxidative stress and inflammation. Curr Pharm Des. 2014;20:3579-94. This review explains the intricate relationship between inflammation and oxidative stress and unravels the complicated mechanisms of oxidative stress in cardiovascular disease.
12. Schiffrin EL. The immune system: role in hypertension. Can J Cardiol. 2013;29:543-8. Schiffrin gives an overview on the recent devlopments in this novel and intriguing research field in cardiovascular medicine.
13. Bene NC, Alcaide P, Wortis HH, Jaffe IZ. Mineralocorticoid receptors in immune cells: emerging role in cardiovascular disease. Steroids. 2014;91:38-45.
14. Kasal DA, Schiffrin EL. Angiotensin II, aldosterone, and anti-inflammatory lymphocytes: interplay and therapeutic opportunities. Int J Hypertens. 2012;2012:829786.
15. De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol. 2005;25:2106-13.
16. Rickard AJ, Morgan J, Chrissobolis S, Miller AA, Sobey CG, Young MJ. Endothelial cell mineralocorticoid receptors regulate DOC/salt-mediated cardiac remodeling and vascular reactivity, but not blood pressure. Hypertension. 2014;63:1033-40.
17. Liu Y, Hirooka K, Nishiyama A, Lei B, Nakamura T, Itano T, et al. Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury. Exp Eye Res. 2012;96:116-23.
18. Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schütz G, et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest. 2010;120:3350-64.
19. Marzolla V, Armani A, Feraco A, De Martino MU, Fabbri A, Rosano G, et al. Mineralocorticoid receptor in adipocytes and macrophages: a promising target to fight metabolic syndrome. Steroids. 2014;91:46-53.
20. Herrada AA, Campino C, Amador CA, Michea LF, Fardella CE, Kalergis AM. Aldosterone as a modulator of immunity: implications in the organ damage. J Hypertens. 2011;29:1684-92. Review of the literature to explain how aldosterone affects the immune system and which implication ensue for cardiovascular disease.
21. Herrada AA, Contreras FJ, Marini NP, Amador CA, González PA, Cortés CM, et al. Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J Immunol. 2010;184: 191-202.
22. Kasal DA, Barhoumi T, Li MW, Yamamoto N, Zdanovich E, Rehman A, et al. T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension. 2012;59:324-30.
23. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation. 2008;117:2253-61.
24. Anders HJ, Schaefer L. Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis. J Am Soc Nephrol. 2014;25: 1387-400. Important revew on the role of the innate immune system in renal and cardiovascular disease. Provides also in-sight into mechanisms of inflammasome and cardiovascular disease.
25. Frantz S, Monaco C, Arslan F. Danger signals in cardiovascular disease. Mediat Inflamm. 2014;2014:395278.
26. Thomas W, Dooley R, Harvey BJ. Aldosterone as a renal growth factor. Steroids. 2010;75:550-4.
27. Dooley R, Harvey BJ, Thomas W. The regulation of cell growth and survival by aldosterone. Front Biosci (Landmark Ed). 2011;16: 440-57.
28. Dooley R, Harvey BJ, Thomas W. Non-genomic actions of aldosterone: from receptors and signals to membrane targets. Mol Cell Endocrinol. 2012;350:223-34.
29. Iraqi W, Rossignol P, Angioi M, Fay R, Nuée J, Ketelslegers JM, et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation. 2009;119:2471-9.
30. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation. 2002;106:2848-53.
31. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. 2015;65:257-63.
32. Vazquez-Rangel A, Soto V, Escalona M, Toledo RG, Castillo EA, Polanco Flores NA, et al. Spironolactone to prevent peritoneal fibrosis in peritoneal dialysis patients: a randomized controlled trial. Am J Kidney Dis. 2014;63:1072-4.
33. Yelken B, Gorgulu N, Gursu M, Yazici H, Caliskan Y, Telci A, et al. Effects of spironolactone on residual renal function and peritoneal function in peritoneal dialysis patients. Adv Perit Dial. 2014;30:5-10.
34. Zhang L, Hao JB, Ren LS, Ding JL, Hao LR. The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis. Lab Invest. 2014;94:839-50.
35. Pizarro M, Solis N, Quintero P, Barrera F, Cabrera D, Rojas-de Santiago P, et al. Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis. Liver Int. 2015;35:2129-38.
36. Mitts TF, Bunda S, Wang Y, Hinek A. Aldosterone and mineralocorticoid receptor antagonists modulate elastin and collagen deposition in human skin. J Invest Dermatol. 2010;130:2396-406.
37. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond). 2007;113:267-78.
38. Rautureau Y, Paradis P, Schiffrin EL. Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells. Steroids. 2011;76:834-9.
39. Lemarié CA, Simeone SM, Nikonova A, Ebrahimian T, Deschênes ME, Coffman TM, et al. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res. 2009;105:852-9.
40. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40:504-10.
41. Kobayashi N, Hara K, Tojo A, Onozato ML, Honda T, Yoshida K, et al. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway. Hypertension. 2005;45:538-44.
42. Nagase M, Fujita T. Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol. 2013;9:86-98.
43. Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int. 2011;79:1051-60.
44. Ritz E, Tomaschitz A. Aldosterone and the kidney: a rapidly moving frontier (an update). Nephrol Dial Transplant. 2014;29:2012-9.
45. Bobadilla NA, Gamba G. New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am J Physiol Renal Physiol. 2007;293:F2-9.
46. Amador CA, Barrientos V, Peña J, Herrada AA, González M, Valdés S, et al. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the down-regulation of regulatory T lymphocytes. Hypertension. 2014;63: 797-803.
47. Waanders F, Rienstra H, Boer MW, Zandvoort A, Rozing J, Navis G, et al. Spironolactoneameliorates transplant vasculopathy inrenal chronic transplant dysfunction in rats. Am J Physiol Renal Physiol. 2009;296:F1072-9.
48. Juncos LA, Juncos LI (2015) Mineralocorticoid receptor antagonism in AKI: a new hope? J Am Soc Nephrol
49. Barrera-Chimal J, Pérez-Villalva R, Rodríguez-Romo R, Reyna J, Uribe N, Gamba G, et al. Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury. Kidney Int. 2013;83:93-103.
50. Sánchez-Pozos K, Barrera-Chimal J, Garzón-Muvdi J, Pérez-Villalva R, Rodríguez-Romo R, Cruz C, et al. Recovery from ischemic acute kidney injury by spironolactone administration. Nephrol Dial Transplant. 2012;27:3160-9.
51. Barrera-Chimal J, Pérez-Villalva R, Ortega JA, Sánchez A, Rodríguez-Romo R, Durand M, et al. Mild ischemic injury leads to long-term alterations in the kidney: amelioration by spironolactone administration. Int J Biol Sci. 2015;11:892-900.
52. Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, Labat C, Benjamin L, Farman N, et al. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J. 2010;24:2454-63.
53. Farman N, Vandewalle A, Bonvalet JP. Autoradiographic study of aldosterone and dexamethasone binding in isolated glomeruli of rabbit kidney. Am J Physiol. 1982;243:F235-42.
54. Lee HA, Song MJ, Seok YM, Kang SH, Kim SY, Kim I. Histone deacetylase 3 and 4 complex stimulates the transcriptional activity of the mineralocorticoid receptor. PLoS ONE. 2015;10, e0136801.
55. Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008;14:1370-6.
56. Quinkler M, Zehnder D, Eardley KS, Lepenies J, Howie AJ, Hughes SV, et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation. 2005;112:1435-43.
57. Huang LL, Nikolic-Paterson DJ, Han Y, Ozols E, Ma FY, Young MJ, et al. Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease. J Am Soc Nephrol. 2014;25: 2231-40.
58. Standards of medical care in diabetes 2014. Diabetes Care 2014;37 Suppl 1:S14-80
59. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3:486-92.
60. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2009:CD007004.
61. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis. 2008;51:199-211.
62. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med. 2001;345:925-6.
63. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended anti-hypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care. 2005;28:2106-12.
64. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41:64-8.
65. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1:940-51.
66. Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2014;4, CD007004.
67. Schwenk MH, Hirsch JS, Bomback AS. Aldosterone blockade in CKD: emphasis on pharmacology. Adv Chronic Kidney Dis. 2015;22:123-32.
68. Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol. 2012;60:2082-9.
69. Rossignol P, Cleland JG, Bhandari S, Tala S, Gustafsson F, Fay R, et al. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Circulation. 2012;125:271-9.
70. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17.
71. Drechsler C, Ritz E, Tomaschitz A, Pilz S, Schönfeld S, Blouin K, et al. Aldosterone and cortisolaffect the risk of suddencardiac death in haemodialysis patients. Eur Heart J. 2013;34:578-87.
72. Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol. 2014;63:528-36.
73. Menard J. The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004;217:45-52.
74. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237:268-75.
75. Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics. Mol Cell Endocrinol. 2012;350:310-7. This review provides an excellent overview of earlynon-steroidal development andrationale from an industry perspective.
76. Rossier BC, Baker ME, Studer RA. Epithelial sodium transport and its control by aldosterone: the story of our internal environment revisited. Physiol Rev. 2015;95:297-340.
77. Parthasarathy HK, Ménard J, White WB, Young Jr WF, Williams GH, Williams B, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29:980-90.
78. Netchitailo P, Delarue C, Perroteau I, Leboulenger F, Capron MH, Vaudry H. Relative inhibitory potency of five mineralocorticoid antagonists on aldosterone biosynthesis in vitro. Biochem Pharmacol. 1985;34:189-94.
79. Ye P, Yamashita T, Pollock DM, Sasano H, Rainey WE. Contrasting effects of eplerenone and spironolactone on adrenal cell steroid-genesis. Horm Metab Res. 2009;41:35-9.
80. Penhoat A, Darbeida H, Bernier M, Saez JM, Durand P. Inhibition of hormonal-induced cAMP and steroid production by inhibitors of pregnenolone metabolism in adrenal and Leydig cells. Mol Cell Endocrinol. 1988;60:55-60.
81. Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, et al. Use of aldosterone antagonists in heart failure. JAMA. 2009;302:1658-65.
82. Amazit L, Le Billan F, Kolkhof P, Lamribet K, Viengchareun S, Fay MR, et al. Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. J Biol Chem. 2015;290(36): 21876-89.
83. Bärfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Pérez S, Heckroth H, et al. Kolkhof P Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385-403.
84. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist bay 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial. Eur Heart J. 2013;34:2453-63.
85. Pitt B, Filippatos G, Gheorghiade M, et al. Rationale and design of arts: A randomized, double-blind study of bay 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail. 2012;14:668-75.
86. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370: 1383-92. This publication is the first to demonstrate effective-ness of non-steroidal MR antagonists in humans.
87. Ruilope LM, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol. 2014;40:572-81.
88. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy:a randomized clinical trial. JAMA. 2015;314: 884-94. First study to demonstrate anti-proteinuric effects of finererone in diabetic patients with nephropathy.
89. Mavrakanas TA, Gariani K, Martin PY. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy. Eur J Int Med. 2014;25(2):173-6.
90. Mehdi UF, Adams-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20(12):2641-50.